Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes

被引：7
|
作者：
Lee, J. -Y. [1 ,2 ]
Cho, Y. [1 ,2 ]
Lee, M. [1 ,2 ]
Lee, Y. -H. [1 ,2 ,3 ]
Lee, B. -W. [1 ,2 ,3 ]
Kang, E. S. [1 ,2 ,3 ]
Cha, B. -S. [1 ,2 ,3 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Grad Sch, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Inst Endocrine Res, Coll Med, Seoul, South Korea
来源：
DIABETES & METABOLISM | 2018年 / 44卷 / 05期
关键词：
INSULIN-RESISTANCE; DOUBLE-BLIND; PIOGLITAZONE; TOLERABILITY; METFORMIN; THERAPY; VILDAGLIPTIN; MONOTHERAPY; 24-WEEK;
D O I：
10.1016/j.diabet.2017.11.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：452 / 455
页数：4
相关论文
共 50 条
  • [41] Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes and metabolic syndrome over 24-weeks
    Kim, D.
    Kim, S.
    Yoon, K.
    Chun, S.
    Park, K.
    Choi, K.
    Lim, S.
    Mok, J.
    Lee, H.
    Seo, J.
    Cha, B.
    Kim, M. -K.
    Shon, H.
    Choi, D.
    DIABETOLOGIA, 2019, 62 : S428 - S428
  • [42] Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
    Kelly, IE
    Han, TS
    Walsh, K
    Lean, MEJ
    DIABETES CARE, 1999, 22 (02) : 288 - 293
  • [43] Thiazolidinedione use and risk of Parkinson's disease in patients with type 2 diabetes mellitus
    Zhao, Houyu
    Zhuo, Lin
    Sun, Yexiang
    Shen, Peng
    Lin, Hongbo
    Zhan, Siyan
    NPJ PARKINSONS DISEASE, 2022, 8 (01)
  • [44] Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus
    Houyu Zhao
    Lin Zhuo
    Yexiang Sun
    Peng Shen
    Hongbo Lin
    Siyan Zhan
    npj Parkinson's Disease, 8
  • [45] Effectiveness and tolerance of exanetide in patients with type 2 diabetes treated with thiazolidinedione associated or not with metformin
    Garcia, S. Duran
    Hoogwerf, B.
    Zinman, B.
    Milton, D.
    Giaconia, J.
    Kinds, D.
    Trautmann, M.
    Brodows, R.
    DIABETES & METABOLISM, 2007, 33 : S120 - S120
  • [46] Efficacy and safety of treatment with simvastatin in thiazolidinedione-treated Type 2 diabetic patients
    Kipnes, MS
    Lewin, AJ
    Meneghini, LF
    Perevozskaya, I
    Shah, S
    Plotkin, D
    Tobert, J
    DIABETOLOGIA, 2002, 45 : A388 - A388
  • [47] Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
    Sabina Yasmin
    Fabio Capone
    Antonio Laghezza
    Fabrizio Dal Piaz
    Fulvio Loiodice
    Viswanathan Vijayan
    Velmurugan Devadasan
    Susanta K. Mondal
    Özlem Atlı
    Merve Baysal
    Ashok K. Pattnaik
    Venkatesan Jayaprakash
    Antonio Lavecchia
    Scientific Reports, 7
  • [48] Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
    Yasmin, Sabina
    Capone, Fabio
    Laghezza, Antonio
    Dal Piaz, Fabrizio
    Loiodice, Fulvio
    Vijayan, Viswanathan
    Devadasan, Velmurugan
    Mondal, Susanta K.
    Atli, Ozlem
    Baysal, Merve
    Pattnaik, Ashok K.
    Jayaprakash, Venkatesan
    Lavecchia, Antonio
    SCIENTIFIC REPORTS, 2017, 7
  • [49] Improvement of Nonalcoholic Fatty Liver Disease with Lobeglitazone in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
    Lee, Yong-Ho
    Jin, Heung Yong
    Rhee, Eun-Jung
    Cho, Young Min
    Kim, Jae Hyeon
    Lee, Byung-Wan
    DIABETES, 2016, 65 : A7 - A7
  • [50] The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
    Yau, Hanford
    Rivera, Kathya
    Lomonaco, Romina
    Cusi, Kenneth
    CURRENT DIABETES REPORTS, 2013, 13 (03) : 329 - 341
12345